Avances en la protección frente a las infecciones por Klebsiella pneumoniae mediante una vacuna de ADN con múltiples antígenos

Mireia López

  • PROJECT LEADER

    Mireia López.

  • APPLICANT INSTITUTION
    AND COUNTRY

    Universitat de Girona, Spain.

  • DESCRIPTION

    Klebsiella pneumoniae is a bacterium that can cause severe pneumonia, sepsis and other life-threatening infections, particularly in people with weakened immune systems and in healthcare settings. Its growing resistance to antibiotics is turning this infection into a major public health concern. This project aims to develop a vaccine that helps prevent infection, reduce disease severity and lower the risk of death.

    KlebsiGene is a vaccine that uses DNA technology to stimulate a strong immune response against the bacterium. The team is improving the vaccine by combining several bacterial components to target multiple strains and by enhancing the delivery system so that it reaches immune cells more effectively. The researchers will test how effectively the vaccine protects against different forms of K. pneumoniae infection.

    An effective vaccine could reduce infection rates and the associated healthcare costs. Importantly, it could also help reduce antibiotic use at a time when antimicrobial resistance is rising. Altogether, KlebsiGene could have a significant impact on public health.

  • PROJECT
    STAGE

    STAGE 2